Paysign, Inc. (PAYS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Paysign, Inc. is a vertically integrated provider of prepaid card products, patient affordability offerings, and digital banking services. The company operates as a single reporting segment, serving industries including plasma, pharmaceuticals, healthcare, hospitality, and retail. As of October 31, 2024, there were 53,548,374 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenues | $15,256,431 | $12,400,325 | $42,778,104 | $33,584,666 |
| Gross Profit | $8,473,314 | $6,332,118 | $22,998,328 | $16,995,527 |
| Gross Margin | 55.5% | 51.1% | 53.8% | 50.6% |
| Net Income | $1,436,837 | $1,100,604 | $2,443,035 | $836,318 |
| Diluted EPS | $0.03 | $0.02 | $0.04 | $0.02 |
| Operating Cash Flow (YTD) | $8,633,922 (2024) vs $4,180,064 (2023) | |||
| Cash & Restricted Cash | $110,565,373 (Sep 30, 2024) | |||
| Unrestricted Cash | $10,293,207 (Sep 30, 2024) | |||
| Customer Card Funding (Liability) | $100,091,865 (Sep 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23.0% in Q3 and 27.4% YTD compared to the prior year.
- Pharma Industry: Revenue surged 219.1% in Q3 and 255.6% YTD, driven by the launch of 32 net new patient affordability programs.
- Plasma Industry: Revenue grew 3.4% in Q3 and 8.7% YTD, attributed to 16 net new plasma centers and increased donation volumes.
- Profitability: Net income increased 30.5% in Q3 and 192.1% YTD. The company turned an operating loss of $799,251 in the first nine months of 2023 into an operating income of $557,174 in the same period of 2024.
- Expense Increases: Operating expenses rose 35.6% in Q3, primarily due to increased compensation and benefits ($1.8M increase) and technology investments ($279k increase). Depreciation and amortization increased 49.8% due to capitalized software development.
- Balance Sheet: Accounts receivable increased significantly to $32.8M (from $16.2M at year-end 2023), largely due to pass-through claims in the pharma business. Customer card funding liabilities grew to $100.1M.
Outlook, Risks, and Contingencies
- Liquidity: Management believes unrestricted cash ($10.3M) and forecasted cash flows are sufficient to sustain operations for the next 24 months. The company plans to continue investing in technology, sales, and cybersecurity.
- Legal Proceedings:
- Securities Class Action: A settlement of $3.75 million was approved in April 2024, fully covered by directors-and-officers insurance.
- Derivative Actions: Four shareholder derivative actions were settled in principle in October 2024. The settlement involves corporate governance changes and $607,500 in attorneys' fees, also covered by insurance.
- Risk Factors: The company notes concentration risk in accounts receivable (two pharma customers represented 38% of receivables) and credit risk regarding cash deposits exceeding FDIC limits, though a deposit swapping program is in place to mitigate this.
- Stock Repurchases: The company repurchased 100,000 shares in Q3 at a weighted average price of $3.60. Approximately $3.51 million remains available under the current $5 million repurchase program.
Investor Verification Checklist
- Verify the sustainability of the 255% YTD growth in the Pharma segment and the associated receivables collection cycle.
- Monitor the impact of rising operating costs (compensation, fraud, network fees) on future gross margins.
- Confirm the final court approval and payment terms of the derivative action settlements.
- Assess the company's ability to maintain liquidity given the high level of restricted cash ($100.3M) versus unrestricted cash ($10.3M).
- Review the progress of the $5 million stock repurchase program and its impact on share count.